Background and purpose: Childhood-onset schizophrenia (COS) is a clinically severe form of schizophrenia, which causes severe impairment to cognitive, linguistic, and social development. There are few prospective and retrospective open clinical trials of risperidone and olanzapine in COS. In this open-label, randomized, prospective study, we compared the tolerability and effectiveness of risperidone versus olanzapine in the treatment of COS patients. Methods: The study population consisted of 25 children with COS (mean age 11.09 ± 1.55 years). After an evaluation, patients received risperidone (0.25-4.5 mg/day, mean dose 1.62 ± 1.02 mg/day) or olanzapine (2.5-20 mg/day, mean dose 8.18 ± 4.41 mg/day) for 12 weeks, with weekly evaluations. Results: Both groups showed comparable significant (p < 0.001) within-group improvement from baseline to endpoint (LOCF) in Positive and Negative Symptoms Scale (PANSS) total and subscale scores. Of the olanzapine-treated children, 11 (91.7%) completed the 12 weeks of the study, whereas in the risperidone-treated children only 9 (69.2%) did. No significant differences between risperidone-treated children and olanzapine-treated children were observed on Barnes Akathisia Rating Scale (BAS) and Simpson-Angus Scale (SAS) rating scales. Both treatment groups showed significant (p < 0.001) increase in weight from baseline to endpoint. Conclusion: Our open-label, small-scale comparative study suggests that both risperidone and olanzapine appear to be efficacious antipsychotic medications in COS, with a slight non-significant advantage of olanzapine in the dropout rate.
|Number of pages||11|
|Journal||Journal of Child and Adolescent Psychopharmacology|
|State||Published - Aug 2006|